InvestmentJul 16, 2026, 03:26 PM
Helus Pharma Raises $50M in Underwritten Public Offering
AI Summary
Helus Pharma (Cybin Inc.) announced and subsequently closed an underwritten public offering, raising approximately US$50 million in aggregate gross proceeds. The company issued 10,309,280 common shares at a price of US$4.85 per share. The net proceeds from this offering are intended to advance its HLP003, HLP004, and HLP005 programs, and for general corporate purposes and working capital.
Key Highlights
- Closed an underwritten public offering of common shares.
- Raised approximately US$50 million in aggregate gross proceeds.
- Issued 10,309,280 common shares in the offering.
- Offering price was US$4.85 per common share.
- Proceeds will fund HLP003, HLP004, and HLP005 programs.
- HLP003 Phase 3 APPROACH data expected in Q4 2026.
Price Impact
More from HELP